F
Financials.page
Company Fundamentals
Workspace
OverviewhomeCompaniesdirectoryAPI & MCPdevelopers
Company financial data, refreshed daily. Not investment advice.
Financials.page — company financial data, refreshed daily. Not investment advice. Legal & terms
Annual figures as reported in 10-K / 20-F / 40-F filings.
UTMD · CIK 0000706698

UTAH MEDICAL PRODUCTS INC

Annual figures as reported, FY2014–FY2025. Ratios and growth rates derived on-page.

UTMD logo
Surgical & Medical Instruments & Apparatus
Company profile
Nasdaq · UTMDHQ Midvale, UTIncorporated in UTFiscal year ends Dec 31Non-accelerated filer Smaller reporting company
Revenue
$38.5M
▼ −5.8% vs FY2024
Net income
$11.3M
▼ −18.7% vs FY2024
Free cash flow
$14.3M
▼ −1.9% vs FY2024
Diluted EPS
$3.48
▼ −12.1% vs FY2024

Revenue

Annual, as reported

020M40M’14’16’18’20’22’24’25$38.5M

Net income

Annual, as reported

05M10M15M’14’16’18’20’22’24’25$11.3M

Recent quarters

momentum · last 12 quarters
Revenue — Mar ’26 quarter
$8.7M
▼ −10.2% vs Mar ’25
Net income — Mar ’26 quarter
$2.6M
▼ −14.4% vs Mar ’25
Revenue — trailing 12 months
$37.5M
▼ −4.4% vs Mar ’25
Diluted EPS — trailing 12 months
$3.38
▼ −10.8% vs Mar ’25

Quarterly revenue

Discrete quarters; Q4 derived from the annual figure

05M10MJun ’23Dec ’23Jun ’24Dec ’24Jun ’25Dec ’25Mar ’26$8.7M

Quarterly net income

Discrete quarters; Q4 derived from the annual figure

02M4MJun ’23Dec ’23Jun ’24Dec ’24Jun ’25Dec ’25Mar ’26$2.6M
QuarterRevenueRev. YoYGross marginNet incomeNet marginDiluted EPS
Mar ’26$8.7M−10.2%60.6%$2.6M29.9%$0.82
Dec ’25$9.0M−1.2%58.2%$2.6M28.4%$0.80
Sep ’25$9.8M−1.9%57.1%$2.6M26.8%$0.82
Jun ’25$10.0M−4.3%56.2%$3.0M30.6%$0.94
Mar ’25$9.7M−14.4%57.0%$3.0M31.3%$0.92
Dec ’24$9.2M−25.8%58.1%$2.9M31.7%$0.86
Sep ’24$10.0M−20.0%58.0%$3.6M35.6%$1.03
Jun ’24$10.4M−19.2%60.1%$3.5M33.2%$0.98

Profitability & returns

quality of earnings

Margins

Share of revenue kept at each line

0%20%40%60%’14’16’18’20’22’24
Gross marginOperating marginNet margin

Returns on capital

Net income vs year-end equity and assets

0%10%20%’14’16’18’20’22’24
Return on equityReturn on assets

Cash flow

cash generation

Free cash flow

Operating cash flow less capital expenditure

010M20M’14’16’18’20’22’24’25$14.3M

Operating cash flow

Net cash from operations

010M20M’14’16’18’20’22’24’25$14.7M

Shareholder returns

capital allocation

Capital returned

Cash paid out as dividends and share repurchases

010M20M’14’16’18’20’22’24’25
Dividends paidBuybacks

Diluted shares outstanding

Falling count means buybacks outpace dilution

01M2M3M’14’16’18’20’22’24’253M

Balance sheet

financial position

Stockholders’ equity

At fiscal year end

050M100M’14’16’18’20’22’24’25$119.3M

Net debt

Long-term debt less cash — negative means net cash

−75M−50M−25M0’14’17’19’21’23’25−$85.8M

Growth rates

compounding, annualized
Revenue CAGR
−9.7%
3y
−1.8%
5y
−0.4%
10y
Net income CAGR
−11.8%
3y
+0.9%
5y
−0.5%
10y
Diluted EPS CAGR
−8.3%
3y
+3.4%
5y
+1.0%
10y
Free cash flow CAGR
−11.0%
3y
−5.8%
5y
+0.5%
10y
Share count change (split-adjusted)
−11.8%
5y
−14.1%
10y

Key ratios

derived per fiscal year
Fiscal yearGross marginOp. marginNet marginFCF marginROEROACurrent ratioDebt / equity
FY202557.1%29.6%29.3%37.2%9.5%9.2%37.62×0.00×
FY202459.0%33.2%33.9%35.7%11.8%11.3%25.64×0.00×
FY202359.8%33.4%33.1%43.1%13.0%12.3%22.56×0.00×
FY202261.6%37.9%31.5%38.9%14.4%13.3%15.09×0.00×
FY202163.0%38.5%30.1%42.1%13.8%12.8%19.53×0.00×
FY202060.6%32.5%25.6%45.7%10.5%9.7%16.42×0.00×
FY201962.8%37.6%31.4%35.2%14.6%13.4%15.92×0.00×
FY201862.6%44.5%44.2%39.1%20.9%18.6%11.58×0.00×
FY201763.7%45.9%20.5%37.0%10.9%9.2%9.32×0.00×
FY201660.3%41.2%30.9%28.6%17.5%15.9%11.41×—
FY201560.2%39.0%29.5%33.9%17.0%15.0%8.08×0.00×
FY201460.5%39.3%27.6%34.6%17.6%14.0%3.31×0.00×

Annual figures

as reported
Fiscal yearRevenueGross profitOp. incomeNet incomeDiluted EPSOp. cash flowCapexTotal assetsLiabilitiesEquityCashLT debt
FY2025$38.5M$22.0M$11.4M$11.3M$3.48$14.7M$371K$122.5M$3.3M$119.3M$85.8M$0
FY2024$40.9M$24.1M$13.6M$13.9M$3.96$14.8M$230K$122.5M$5.1M$117.4M$83.0M$0
FY2023$50.2M$30.0M$16.8M$16.6M$4.57$22.3M$639K$135.5M$7.1M$128.3M$92.9M$0
FY2022$52.3M$32.2M$19.8M$16.5M$4.52$21.1M$809K$123.9M$9.6M$114.3M$75.1M$0
FY2021$49.1M$30.9M$18.9M$14.8M$4.04$21.2M$552K$115.6M$8.5M$107.1M$61.0M$0
FY2020$42.2M$25.5M$13.7M$10.8M$2.94$20.1M$860K$111.7M$8.9M$102.8M$51.6M$0
FY2019$46.9M$29.5M$17.6M$14.7M$3.94$17.1M$540K$109.8M$8.7M$101.1M$42.8M$0
FY2018$42.0M$26.3M$18.7M$18.6M$4.95$16.8M$402K$99.8M$10.8M$89.0M$51.1M$0
FY2017$41.4M$26.4M$19.0M$8.5M$2.28$16.9M$1.6M$92.7M$14.6M$78.1M$39.9M$0
FY2016$39.3M$23.7M$16.2M$12.1M$3.22$14.5M$3.3M$76.2M$6.9M$69.2M$26.3M—
FY2015$40.2M$24.2M$15.7M$11.8M$3.14$13.8M$176K$79.2M$9.5M$69.6M$23.3M$1K
FY2014$41.3M$25.0M$16.2M$11.4M$3.02$15.4M$1.1M$81.1M$16.5M$64.6M$19.3M$5K

Latest filings

the most recent regulatory filings
4PRIMARY DOCUMENT2026-07-01 ↗4PRIMARY DOCUMENT2026-05-29 ↗SDUTAH MEDICAL FORM SD2026-05-27 ↗SCHEDULE 13G/ASEC filing2026-05-14 ↗10-QUTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING2026-05-12 ↗8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING2026-05-04 ↗8-KUTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING2026-04-23 ↗DEF 14APROXY STATEMENT2026-04-02 ↗10-KUTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING2026-03-27 ↗SCHEDULE 13G/ASEC filing2026-03-27 ↗

Company logos by Elbstream and unavatar.

All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.